Possible Links between Sickle Cell Crisis and Pentavalent Antimony

Garcerant, Daniel; Rubiano, Luisa; Blanco, V. M.; Martínez, Javier Rúiz; Baker, Nancy C.; Craft, Noah

doi:10.4269/ajtmh.2012.11-0683

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meglumine antimoniate for the treatment of CL seems to reduce blood cell counts and liver enzymes more frequently in children than in adults and appears to signifi cantly increase serum amylase and lipase levels 43 . A sickle cell crisis has been reported as an adverse effect of CL treatment with meglumine antimoniate in a 6-year-old child in Colombia 44 . Intra-lesional meglumine antimoniate seems to be an alternative for children with CL.…”

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 46(6):669-677, Nov-Dec, 2013http://dx.doi. org/10.1590/0037-8682-0104-2013 Address to: Dr a Juliana Saboia Fontenele e Silva. Lab. ABSTRACT We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fi ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.

show abstract

Section: Resultsmentioning

confidence: 99%